timolol   Click here for help

GtoPdb Ligand ID: 565

Synonyms: Timoptic®
Approved drug PDB Ligand  verified structure
timolol is an approved drug (FDA (1981))
Compound class: Synthetic organic
Comment: Marketed formulations may contain timolol maleate (PubChem CID 5281056).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 107.98
Molecular weight 316.16
XLogP 1.28
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(COc1nsnc1N1CCOCC1)CNC(C)(C)C
Isomeric SMILES O[C@H](COc1nsnc1N1CCOCC1)CNC(C)(C)C
InChI InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1
InChI Key BLJRIMJGRPQVNF-JTQLQIEISA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Baker JG. (2005)
Evidence for a secondary state of the human beta3-adrenoceptor.
Mol Pharmacol, 68 (6): 1645-55. [PMID:16129733]
2. Baker JG. (2005)
Site of action of beta-ligands at the human beta1-adrenoceptor.
J Pharmacol Exp Ther, 313 (3): 1163-71. [PMID:15716385]
3. Baker JG. (2005)
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
Br J Pharmacol, 144 (3): 317-22. [PMID:15655528]
4. Baker JG. (2010)
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors.
PLoS ONE, 5 (11): e15487. [PMID:21152092]
5. Baker JG. (2026)
Comparing the Molecular Pharmacological Properties of Existing β-Blockers to Determine the Theoretically Most "Ideal" Anti-Cancer β-Blocker.
Pharmacol Res Perspect, 14 (1): e70214. [PMID:41485077]
6. Baker JG, Fromont C, Bruder M, Thompson KSJ, Kellam B, Hill SJ, Gardiner SM, Fischer PM. (2020)
Using Esterase Selectivity to Determine the In Vivo Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers.
ACS Pharmacol Transl Sci, 3 (4): 737-748. [PMID:32832874]
7. Baker JG, Hall IP, Hill SJ. (2003)
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Mol Pharmacol, 64 (6): 1357-69. [PMID:14645666]
8. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ. (2004)
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
Naunyn Schmiedebergs Arch Pharmacol, 369 (5): 525-32. [PMID:15060759]